Blood and scans may predict chemo success in breast cancer

NCT ID NCT07610525

Not yet recruiting Knowledge-focused Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen May 30, 2026 · Last updated Jun 14, 2026 · Updated 5 times

Summary

This study looks at whether blood tests and imaging scans can show if early-stage triple-negative breast cancer has fully responded to chemotherapy before surgery. About 200 people will receive standard chemo plus immunotherapy, and researchers will check if these tests can accurately predict a complete response. The goal is to see if some people might avoid surgery in the future.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

MD Anderson Cancer Center

Houston, Texas, 77030, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

BLOOD AND IMAGE GUIDED OPTIMIZATION OF NEOADJUVANT THERAPY PHASE 2 TRIPLE NEGATIVE BREAST CANCER

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.

EARLY STAGE TRIPLE NEGATIVE BREAST CANCER